Johnson and Johnson to submit single-dose COVID-19 vaccine trial data: Bloomberg
New Delhi: Johnson & Johnson's preliminary data from the South African arm of a phase 3 Covid-19 vaccine trial will be ready for submission to U.S. regulators by Jan. 21, according to the head of the country's Medical Research Council.
The timing ties in with the U.S. drug giant's statement that interim data from the late-stage trial it is conducting in a number of countries is expected by the end of this month. If the data show the one-dose vaccine to be safe and effective, J&J will approach U.S. regulators for an emergency use authorization in February, and "other health regulatory applications around the world will be made in parallel," according to the company.
Moncef Slaoui, the chief scientific adviser to the U.S. Operation Warp Speed program, has said the emergency clearance could be granted by U.S. regulators by early February.
Read also: JnJ enrolls about 45,000 participants for COVID vaccine late-stage trial
J&J is one of four vaccine developers running late-stage trials in South Africa. Business Day, a Johannesburg-based newspaper, reported the planned timing of the data submission earlier. It was confirmed by Glenda Gray, president of the research council and co-chair of the local study.
J&J has signed an agreement under which Aspen Pharmacare Holdings Ltd. will manufacture 300 million doses a year in South Africa if the vaccine is approved.
Read also: COVID-19 vaccine main candidates - Where they stand
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.